solution by Industry

Integrated Bioprocessing Systems & Turnkey Biopharmaceutical Factory Solutions

From bioreactors and aseptic filling lines to cleanroom and water systems — complete GMP-compliant manufacturing infrastructure for biologics producers worldwide.

Industry Overview

The Industry at a Glance

The global biopharmaceutical manufacturing market reached $449.9 billion in 2024 and is projected to hit $967.7 billion by 2033, growing at a CAGR of 8.9%. Asia-Pacific is poised to grow at the fastest CAGR of 21.6%, driven by increasing healthcare access and technological advancements. With expanding biosimilar pipelines, rising demand for monoclonal antibodies, and government-backed capacity build-outs across emerging markets, manufacturers need scalable, GMP-ready bioprocessing infrastructure — from upstream cell culture through aseptic fill-finish.

Product Applications

Where Our Products Are Used

  • 1

    IV Infusion Production Lines

    Complete systems for Non-PVC soft bag, PP bottle, and glass bottle IV solutions, from compounding to filling and sterilization.
  • 2

    Ampoule & Vial Filling Lines

    High-speed aseptic filling and sealing lines for injectable formulations, fully compliant with cGMP requirements.
  • 3

    Oral Solid Dosage (OSD) Plants

    Integrated granulation, tablet pressing, capsule filling, coating, and blister packaging for tablets and capsules.
  • 4

    Pharmaceutical Water Treatment Systems

    Purified water (PW) and water for injection (WFI) generation, storage, and distribution systems meeting pharmacopeia standards.
  • 5

    Cleanroom & HVAC Engineering

    Full facility design including classified cleanrooms, HVAC zoning, and environmental monitoring systems.

technology

Pain Points & Solutions

  • Pain Point: Building bioprocessing capacity from scratch demands coordinating dozens of specialized vendors.

    Solution: Single-source turnkey delivery — bioreactors, fill-finish lines, water systems, cleanrooms, and packaging integrated under one engineering contract.

  • Pain Point: Regulatory complexity across multiple markets delays facility approval and product launch.

    Solution: All systems pre-engineered to EU GMP, US FDA cGMP, WHO GMP, and PIC/S standards — designed to pass multi-agency audits.

  • Pain Point: Rapid scale-up from clinical-stage to commercial production without quality drift.

    Solution: Modular, scalable system architecture with full IQ/OQ/PQ validation ensures consistent output from pilot batches to full-scale manufacturing.

Advantages

Why Choose Us

  • 2,500+ production lines and 40+ turnkey projects delivered across 60+ countries

  • Near 20 years of pharmaceutical and bioprocessing engineering expertise

  • 4 self-owned factories — pharma machinery, water treatment, cleanroom systems, and automated packaging under vertical quality control

  • End-to-end project scope — consulting, process design, equipment manufacturing, installation, validation, technology transfer, and operator training

  • Multi-standard GMP compliance (EU, FDA, WHO, PIC/S) embedded in every deliverable

  • Customized bioprocessing configurations matched to each client’s product portfolio, regulatory environment, and facility constraints

case

Success Snapshot

  • National Vaccine Manufacturer

    North Africa

    Delivered a complete biologics production facility including bioreactor systems, aseptic vial filling line, WFI system, and cleanroom. The facility achieved WHO GMP prequalification within 6 months of commissioning, enabling domestic vaccine supply for national immunization programs.

  • Emerging Biotech Company

    Middle East

    Designed and installed a turnkey monoclonal antibody production workshop — from upstream bioprocessing through fill-finish and packaging. Production capacity reached 2 million vials/year, and the client secured regional regulatory approval on the first submission.

testimony

Trusted by Industry Leaders

  • “IVEN handled the full scope — bioreactors, water for injection, cleanroom, and filling lines — all validated to WHO GMP. We couldn’t have built this facility without a single integrated partner.”

    Dr. H

    Technical Director

  • “Their engineering team understood our biologics process requirements from day one. The facility was delivered on schedule and passed our regulatory inspection without a single major finding.”

    Mr. S

    VP of Manufacturing

Support

FAQ

Monoclonal antibodies, recombinant proteins, vaccines, and other injectable biologics — from upstream bioprocessing through aseptic fill-finish.

Yes. We configure stainless-steel, single-use, or hybrid systems based on your product requirements, batch size, and facility strategy.

All projects are designed to simultaneously comply with EU GMP, US FDA cGMP, WHO GMP, and PIC/S GMP standards.

Most turnkey biopharmaceutical projects are completed within 14–24 months from contract signing to validated production handover.

Yes — including remote diagnostics, preventive maintenance, spare parts logistics, process optimization consulting, and on-site technical service.

Related Industry Solutions